**Prior Authorization DRUG Guidelines**

**LETAIRIS (ambrisentan)**

Effective Date: 10/20/14  
Date Developed: 10/14/14  
Last Approval Date: 01/26/16, 01/24/17, 1/23/18

**Description:** Letairis is an endothelin receptor antagonist selective for the endothelin type-A (ETA) receptor. This prevents the action of a potent paracrine peptide on the ETA receptor which leads to vasodilatation.

**Authorization Criteria:** Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I to improve exercise ability and delay clinical worsening.

**Dosing:** 5mg once daily, up to maximum of 10 mg daily

**How Supplied:** Tablets 5mg and 10mg

**Contraindications/Warnings:** Contraindicated in pregnancy; avoid grapefruit

**Major Adverse Reactions:** Pulmonary edema with pulmonary veno-occlusive disease (PVOD); decreased sperm count; decreased hemoglobin; fluid retention

**Major Drug Interactions:** Use caution with other vasodilators

---

**REFERENCES**


Revision History:

Date Approved by P&T Committee: 10/28/14; QA Committee: 11/25/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>